Wu Y - Search Results

1

Identification of Ferroptosis-Related Prognostic Signature and Subtypes Related to the Immune Microenvironment for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.

Xu Y, Du Y, Zheng Q, Zhou T, Ye B, Wu Y, Xu Q, Meng X. Xu Y, et al. Among authors: wu y. Front Immunol. 2022 May 4;13:895110. doi: 10.3389/fimmu.2022.895110. eCollection 2022. Front Immunol. 2022. PMID: 35603151 Free PMC article.

2

Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.

Guan D, Jie Q, Wu Y, Xu Y, Hong W, Meng X. Guan D, et al. Among authors: wu y. World J Surg Oncol. 2022 Sep 29;20(1):326. doi: 10.1186/s12957-022-02787-9. World J Surg Oncol. 2022. PMID: 36175898 Free PMC article.

3

Z-Guggulsterone Induces Cell Cycle Arrest and Apoptosis by Targeting the p53/CCNB1/PLK1 Pathway in Triple-Negative Breast Cancer.

Wu Y, Zhou T, Qian D, Liu X, Xu Y, Hong W, Meng X, Tang H. Wu Y, et al. ACS Omega. 2023 Jan 3;8(2):2780-2792. doi: 10.1021/acsomega.2c07480. eCollection 2023 Jan 17. ACS Omega. 2023. PMID: 36687039 Free PMC article.

4

OTUD1 chemosensitizes triple-negative breast cancer to doxorubicin by modulating P16 expression.

Zhou T, Wu Y, Qian D, Tang H, Liu X, Qiu J, Wang D, Hong W, Meng X, Zheng Q. Zhou T, et al. Among authors: wu y. Pathol Res Pract. 2023 Jul;247:154571. doi: 10.1016/j.prp.2023.154571. Epub 2023 May 26. Pathol Res Pract. 2023. PMID: 37257246

5

Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis.

Qian D, Xu Y, Wu Y, Qiu J, Hong W, Meng X. Qian D, et al. Among authors: wu y. Chin Med J (Engl). 2023 Jul 20;136(14):1663-1670. doi: 10.1097/CM9.0000000000002631. Epub 2023 Jun 7. Chin Med J (Engl). 2023. PMID: 37279392 Free PMC article.

6

Hsa-miR-105-5p acts as an oncogene in triple-negative breast cancer.

Qian D, Zhou T, Xiong H, Xu Y, Qiu J, Wu Y, Hong W, Meng X. Qian D, et al. Among authors: wu y. Chin Med J (Engl). 2023 Dec 20;136(24):3022-3024. doi: 10.1097/CM9.0000000000002689. Epub 2023 Jul 18. Chin Med J (Engl). 2023. PMID: 37464455 Free PMC article. No abstract available.

7

Drug therapy for myocarditis induced by immune checkpoint inhibitors.

Wu Y, Xu Y, Xu L. Wu Y, et al. Front Pharmacol. 2023 May 25;14:1161243. doi: 10.3389/fphar.2023.1161243. eCollection 2023. Front Pharmacol. 2023. PMID: 37305530 Free PMC article. Review.

8

Utilizing a Combination of Network Pharmacology and Experimental Validation to Unravel the Mechanism by Which Kuanxiongzhuyu Decoction Ameliorates Myocardial Infarction Damage.

Wu Y, Li M, Chen L, Xu L, Xu Y, Zhong Y. Wu Y, et al. Medicina (Kaunas). 2023 Sep 28;59(10):1740. doi: 10.3390/medicina59101740. Medicina (Kaunas). 2023. PMID: 37893458 Free PMC article.

9

Twice-daily rivaroxaban after percutaneous left atrial appendage closure for atrial fibrillation.

Pan YQ, Jin LS, Qian S, Jiang T, Wang ZN, Chen YL, Qiu YX, Wu YH, Fu JY, Li L, Lin YN, Li YC. Pan YQ, et al. Front Pharmacol. 2024 Feb 22;15:1344828. doi: 10.3389/fphar.2024.1344828. eCollection 2024. Front Pharmacol. 2024. PMID: 38455964 Free PMC article.

10

Lycium barbarum polysaccharide protects rats and cardiomyocytes against ischemia/reperfusion injury via Nrf2 activation through autophagy inhibition.

Pan H, Niu L, Wu Y, Chen L, Zhou X, Zhao Y. Pan H, et al. Among authors: wu y. Mol Med Rep. 2021 Nov;24(5):778. doi: 10.3892/mmr.2021.12418. Epub 2021 Sep 9. Mol Med Rep. 2021. PMID: 34498711 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

85,474 results

Search Page

Filters